MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics reported leadership changes in its finance function. Effective March 13, 2026, the board appointed Melissa Orilall, currently Vice President, Global Financial Operations at Agenus Inc., as Principal Financial Officer, and Austin Charette, Senior Director, Financial Reporting and Compliance at Agenus, as Principal Accounting Officer.
Both executives provide services to MiNK through an Amended and Restated Intercompany Services Agreement with Agenus and do not receive compensation directly from MiNK. The company states there were no new or modified arrangements tied to these designations, and neither appointee has disclosable family relationships or related-party transactions with MiNK’s directors or executive officers.
MiNK Therapeutics, Inc. director Barbara Ryan reported open-market sales of 1,500 shares of Common Stock. The transactions occurred on March 9–10, 2026 at prices between 10.1725 and 15.5652 per share. After these sales, she directly holds 20,406 shares of MiNK Therapeutics common stock.
According to the footnote, the shares sold were originally received as compensation for her services on the company’s Board of Directors, indicating the activity relates to monetizing equity-based director compensation rather than exercising options or derivatives.
MiNK Therapeutics, Inc. director Ryan Barbara reported selling a total of 500 shares of common stock in open-market transactions. The sales occurred on February 27, 2026 for 400 shares at $10.8583 per share and on March 2, 2026 for 100 shares at $10.8258 per share. After these trades, Barbara directly owned 21,906 shares of MiNK Therapeutics common stock.
MiNK Therapeutics, Inc. disclosed an amended insider trading report for its chief executive officer. The amendment updates a prior Form 4 to include 10,024 shares of common stock that were withheld on January 2, 2026 to cover withholding taxes related to stock issued to the executive. These shares were not originally shown in Table I of the earlier filing. After this tax withholding transaction at a reported price of $11.12 per share, the executive beneficially owns 57,942 shares of MiNK Therapeutics common stock in direct ownership. The amendment is described as correcting an error in the original Form 4 filed on January 6, 2026.
MiNK Therapeutics, Inc. reported that Chief Executive Officer Jennifer Buell received new equity awards. On January 2, 2026, she was granted 50,000 stock options with an exercise price of $11.12 per share, exercisable over a three-year vesting schedule, with one-third vesting on the one-year anniversary of the grant date and the remainder in eight equal quarterly installments.
On the same date, she also acquired 31,474 shares of common stock as her 2025 performance bonus, valued at $11.12 per share, which was the fair market value on the issuance date. These bonus shares are fully vested but subject to a lockup, with 100% of the award released on February 2, 2026. Following the stock grant, she directly owned 67,966 common shares.
MiNK Therapeutics director Ryan Barbara received a grant of 5,395 stock options on January 2, 2026. The options give the right to buy common stock at an exercise price of $11.12 per share and expire on February 2, 2036. According to the vesting terms, the option vests on February 2, 2026, provided Barbara continues to serve on the company’s board of directors through that date. After this grant, Barbara beneficially owns 5,395 derivative securities directly.
MiNK Therapeutics director Brian Corvese received a new stock option grant. On January 2, 2026, he was awarded options to buy 5,395 shares of MiNK Therapeutics common stock at an exercise price of $11.12 per share. These options vest on February 2, 2026, as long as he continues to serve on the company’s board through that date. The options expire on January 2, 2036, and were acquired at a price of $0.00, reflecting a compensatory equity award rather than a market purchase.
MiNK Therapeutics director reports new stock-based compensation. A company director received 1,263 restricted stock units (RSUs) of MiNK Therapeutics, Inc. common stock on 12/01/2025 at a value of $11.09 per share. These RSUs were granted in lieu of cash retainers for board and committee service and will vest one month after the grant date, at which point each RSU converts into one share of common stock. After this grant, the director beneficially owns 20,234 shares directly and 27,830 shares indirectly through an irrevocable trust established for the benefit of the director’s family.
MiNK Therapeutics (INKT) filed its Q3 2025 10‑Q, reporting continued losses and a going concern disclosure. Net loss was $2.89M for the quarter and $9.89M year‑to‑date. Cash and cash equivalents were $14.28M as of September 30, 2025.
The company raised liquidity via its at‑the‑market program, selling about 488,000 shares in Q3 for net proceeds of $13.14M, and an additional ~88,000 shares for $1.2M through November 13, 2025. A related party convertible note carried $5.0M principal and ~$154,000 accrued interest, with fair value of ~$5.7M at quarter‑end. Due to related parties totaled $15.04M.
Operating expenses reflected R&D of $1.14M and G&A of $1.85M for Q3. Net cash used in operations was $3.85M for the nine months. The company executed a 1‑for‑10 reverse stock split effective January 28, 2025, regained Nasdaq MVLS compliance on July 28, 2025, and is no longer a Nasdaq “Controlled Company.” Shares outstanding were 4,694,155 as of November 13, 2025. Management states substantial doubt exists about continuing as a going concern for one year after filing, while pursuing financing and partnerships.
MiNK Therapeutics filed a shelf registration to offer up to $150,000,000 of common stock, preferred stock, warrants, debt securities, and units. A related prospectus supplement establishes an at‑the‑market (ATM) program to sell up to $50,000,000 of common stock through B. Riley Securities, Inc.
Sales under the ATM are constrained by General Instruction I.B.6; based on a public float of $35,031,699 as of November 6, 2025, MiNK may currently sell up to $6,641,284 under the ATM. The Sales Agent’s compensation is 3.0% of gross proceeds. The company may sell directly, through agents, or via underwriters as described in the plan of distribution.
MiNK intends to use any net proceeds for working capital and general corporate purposes, including research and development, clinical programs, potential in‑licensing or acquisitions, collaborations, and capital expenditures.